New drug cocktail aims to shrink stomach tumors before surgery
NCT ID NCT07314203
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether adding an immunotherapy drug (adebrelimab) and a targeted therapy (apatinib) to standard chemotherapy (SOX) can improve outcomes for people with locally advanced stomach cancer that cannot be removed right away. The study will enroll 118 participants and measure how often the cancer completely disappears after treatment. The goal is to see if this combination can make surgery more effective and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
adebrelimab (immunotherapy), apatinib mesylate (targeted therapy), and SOX chemotherapy (S-1 and oxaliplatin)
What this could lead to
If successful, this could improve the chance of eliminating visible cancer before surgery, potentially leading to better long-term outcomes for people with locally advanced gastric cancer.
What could go wrong
This is a Phase 3 trial, but it is not yet recruiting and has only 118 participants. Adding multiple drugs may increase side effects, and the benefit over standard treatment is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SURGERY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••